With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Stifel's earnings can be cyclical, with major drivers being securities price levels that affect client assets, capital markets activity, and interest rates. Stifel is an experienced acquirer, but no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback